Annual report of national clinical database-breast cancer registry in 2023: systemic therapy for small breast cancer - PubMed
5 hours ago
- #Breast Cancer Registry
- #Systemic Therapy
- #Japan
- The report provides 2023 nationwide statistics from Japan's National Clinical Database-Breast Cancer Registry.
- Among 107,372 breast cancer patients, 99.3% were female with a median age of 62 years.
- Clinical stage distribution: Stage 0 (15.5%), Stage I (42.1%), Stage II (31.1%), Stage III (7.0%), Stage IV (2.1%).
- Receptor positivity rates: ER (78.9%), PR (70.0%), HER2 (13.3%).
- Among patients without distant metastases, 41.2% underwent breast-conserving surgery, 76.5% sentinel lymph node biopsy, and 6.0% breast reconstruction.
- Radiotherapy distribution: whole-breast irradiation (75.2%), chest-wall irradiation (15.7%), regional irradiation (20.7%).
- For pT1abN0M0 breast cancer, systemic therapy varied: 92.4% of HR-positive/HER2-negative received endocrine therapy, 46.9% of HER2-positive received chemotherapy/anti-HER2 therapy, and 31.2% of HR-negative/HER2-negative received chemotherapy.
- The report highlights risk-adapted, subtype-specific systemic therapy patterns in small breast cancer in Japan.